United Therapeutics Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +5.9%
EBITDA: +5.9%
EBIT: +2.4%
EPS: +8.0%
Free cash flow: -9.9%
Operating cash flow: +10.7%

Forward estimates

Revenue: +7.1%
EBITDA: +36.1%
EPS: -48.8%

Three-year CAGR

Revenue: +18.0%
EBITDA: +20.5%
EBIT: +15.7%
Net income: +22.4%
EPS: +23.5%
Free cash flow: +16.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.